Cargando…
Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma
Molnupiravir is an antiviral drug against viral RNA polymerase activity approved by the FDA for the treatment of COVID-19, which is metabolized to β-D-N4-hydroxycytidine (NHC) in human blood plasma. A novel method was developed and validated for quantifying NHC in human plasma within the analytical...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525314/ https://www.ncbi.nlm.nih.gov/pubmed/37760797 http://dx.doi.org/10.3390/biomedicines11092356 |
_version_ | 1785110754306818048 |
---|---|
author | Komarov, Timofey Karnakova, Polina Archakova, Olga Shchelgacheva, Dana Bagaeva, Natalia Popova, Mariia Karpova, Polina Zaslavskaya, Kira Bely, Petr Shohin, Igor |
author_facet | Komarov, Timofey Karnakova, Polina Archakova, Olga Shchelgacheva, Dana Bagaeva, Natalia Popova, Mariia Karpova, Polina Zaslavskaya, Kira Bely, Petr Shohin, Igor |
author_sort | Komarov, Timofey |
collection | PubMed |
description | Molnupiravir is an antiviral drug against viral RNA polymerase activity approved by the FDA for the treatment of COVID-19, which is metabolized to β-D-N4-hydroxycytidine (NHC) in human blood plasma. A novel method was developed and validated for quantifying NHC in human plasma within the analytical range of 10–10,000 ng/mL using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) to support pharmacokinetics studies. For sample preparation, the method of protein precipitation by acetonitrile was used, with promethazine as an internal standard. Chromatographic separation was carried out on a Shim-pack GWS C18 (150 mm × 4.6 mm, 5 μm) column in a gradient elution mode. A 0.1% formic acid solution in water with 0.08% ammonia solution (eluent A, v/v) and 0.1% formic acid solution in methanol with 0.08% ammonia solution mixed with acetonitrile in a 4:1 ratio (eluent B, v/v) were used as a mobile phase. Electrospray ionization (ESI) was used as an ionization source. The developed method was validated in accordance with the Eurasian Economic Union (EAEU) rules, based on the European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines for the following parameters and used within the analytical part of the clinical study of molnupiravir drugs: selectivity, suitability of standard sample, matrix effect, calibration curve, accuracy, precision, recovery, lower limit of quantification (LLOQ), carryover, and stability. |
format | Online Article Text |
id | pubmed-10525314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105253142023-09-28 Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma Komarov, Timofey Karnakova, Polina Archakova, Olga Shchelgacheva, Dana Bagaeva, Natalia Popova, Mariia Karpova, Polina Zaslavskaya, Kira Bely, Petr Shohin, Igor Biomedicines Article Molnupiravir is an antiviral drug against viral RNA polymerase activity approved by the FDA for the treatment of COVID-19, which is metabolized to β-D-N4-hydroxycytidine (NHC) in human blood plasma. A novel method was developed and validated for quantifying NHC in human plasma within the analytical range of 10–10,000 ng/mL using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) to support pharmacokinetics studies. For sample preparation, the method of protein precipitation by acetonitrile was used, with promethazine as an internal standard. Chromatographic separation was carried out on a Shim-pack GWS C18 (150 mm × 4.6 mm, 5 μm) column in a gradient elution mode. A 0.1% formic acid solution in water with 0.08% ammonia solution (eluent A, v/v) and 0.1% formic acid solution in methanol with 0.08% ammonia solution mixed with acetonitrile in a 4:1 ratio (eluent B, v/v) were used as a mobile phase. Electrospray ionization (ESI) was used as an ionization source. The developed method was validated in accordance with the Eurasian Economic Union (EAEU) rules, based on the European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines for the following parameters and used within the analytical part of the clinical study of molnupiravir drugs: selectivity, suitability of standard sample, matrix effect, calibration curve, accuracy, precision, recovery, lower limit of quantification (LLOQ), carryover, and stability. MDPI 2023-08-23 /pmc/articles/PMC10525314/ /pubmed/37760797 http://dx.doi.org/10.3390/biomedicines11092356 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Komarov, Timofey Karnakova, Polina Archakova, Olga Shchelgacheva, Dana Bagaeva, Natalia Popova, Mariia Karpova, Polina Zaslavskaya, Kira Bely, Petr Shohin, Igor Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma |
title | Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma |
title_full | Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma |
title_fullStr | Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma |
title_full_unstemmed | Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma |
title_short | Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma |
title_sort | development and validation of a high-performance liquid chromatography with tandem mass spectrometry (hplc-ms/ms) method for quantification of major molnupiravir metabolite (β-d-n4-hydroxycytidine) in human plasma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525314/ https://www.ncbi.nlm.nih.gov/pubmed/37760797 http://dx.doi.org/10.3390/biomedicines11092356 |
work_keys_str_mv | AT komarovtimofey developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT karnakovapolina developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT archakovaolga developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT shchelgachevadana developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT bagaevanatalia developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT popovamariia developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT karpovapolina developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT zaslavskayakira developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT belypetr developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma AT shohinigor developmentandvalidationofahighperformanceliquidchromatographywithtandemmassspectrometryhplcmsmsmethodforquantificationofmajormolnupiravirmetabolitebdn4hydroxycytidineinhumanplasma |